CHAPEL HILL, N.C., July 7 /PRNewswire/ -- The growing importance of the medical affairs function coincides with a company's need to manage rapidly changing regulatory requirements in today's biopharmaceutical industry. This year, 32 percent of companies anticipate an increase in medical affairs funding of more than 10 percent. However a top challenge still on the minds of medical affairs executives is insufficient resources, including budget and headcount, for developing & maintaining an effective medical affairs group.
"Medical Affairs Resources, Structures & Trends," conducted for a partner of Best Practices, LLC, provides medical affairs executives with recent trends in budget and staffing resources, key challenges and top success factors for the function.
Download a complimentary white paper at http://www3.best-in-class.com/rr1010.htm that includes selected best practices drawn from extensive primary research with executives from 25 leading companies including, AstraZeneca, Pfizer, Genentech, Amgen, Bristol-Myers Squibb and Novo Nordisk.
Key topics of this primary research include:
The full 40-page report contains more than 100 benchmark metrics and 20 executive narratives, providing medical affairs executives with recent trends in budget and staffing resources, key challenges and top success factors for the function.
For more information on this study or other recent primary research studies, contact us at 919-403-0251 or at firstname.lastname@example.org.
BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.
|SOURCE Best Practices, LLC|
Copyright©2010 PR Newswire.
All rights reserved